How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?

PURPOSE: The US Food and Drug Administration (FDA) communicated the potential cardiovascular risk of thiazolidinediones (rosiglitazone and pioglitazone) in 2007 and required a Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone in 2010. It also communicated in 2010 the potential risk of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Ther
Hlavní autoři: Hsu, Jason C., Ross-Degnan, Dennis, Wagner, Anita K., Zhang, Fang, Lu, Christine Y.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5201140/
https://ncbi.nlm.nih.gov/pubmed/25976425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.04.006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky